Icon

KYGEVVI (NDA219792)- (2GM/PACKET;2GM/PACKET)

DOXECITINE; DOXRIBTIMINE UCB INC
2GM/PACKET;2GM/PACKET
No Yes
2040-Aug-19 2030-Nov-03
None None
None No
KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
0 0 0
Total Other Developers None
Drugs with Suitability No
2GM/PACKET;2GM/PACKET ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.